Uygun V, Karasu G, Daloğlu H, et al. - This is the largest series to be conducted among children to assess ruxolitinib effectiveness with steroid-refractory acute or chronic graft-versus-host disease (GVHD), the main cause of morbidity and mortality in patients who undergo allogeneic hematopoietic stem cell transplantation. The sample consisted of 29 children with steroid-refractory acute or chronic GVHD. The authors discovered that patients treated with ruxolitinib had a high overall response rate for steroid-refractory acute and chronic pediatric GVHD, with the additional benefit of steroid sparing.